Assignment and licensing are two ways a company can come to use intellectual property, and they are not close substitutes. Assignment transfers ownership: the IP becomes the company’s asset, to defend, license out, or sell. A license grants permission to use IP that someone else continues to own, on whatever terms the licensor sets. Founders and investors generally want the company’s core technology assigned to it; licensing is acceptable for peripheral or genuinely third-party IP, and sometimes unavoidable when a university owns the underlying research.
When the IP arrives by license, the terms decide how much it is worth. Exclusivity is first: an exclusive license behaves much more like ownership than a non-exclusive one, which lets the licensor grant the same rights to competitors. Then scope: is it worldwide, does it cover the full field of use the business needs, can the company sublicense. Then durability: can the licensor terminate, are there diligence milestones, what happens to the license in an acquisition (some terminate on change of control, which can poison an exit). And finally cost: upfront fees, running royalties, and any equity or milestone rights that tax every future dollar.
For an investor the practical rule is simple. Assigned, owned core IP is the strongest position. An exclusive, worldwide, broad, durable license is a close second. A non-exclusive, narrow, terminable, or royalty-heavy license to the company’s central technology is a structural weakness that shapes valuation and can complicate or block an exit, no matter how good the science is. This is one of the first things a deep tech diligence reads in the data room, and one of the most expensive to fix after the fact.